In a study, approximately 14.9% of advanced NSCLC patients with EGFR mutations progressed under TKI treatment and developed resistance by acquiring at least one additional genetic mutation in the PI3K pathway, such as PIK3CA, PTEN, and AKT1 [100]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.